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Background: The role of bivalirudin monotherapy in patients undergoing percutaneous coronary intervention (PCI) has been studied extensively in 
randomized trials, although ,,real-world“ clinical data are scarce.
methods: In a retrospective analysis antithrombotic therapy and baseline variables were evaluated in 1,201 consecutive patients admitted with an 
acute coronary syndrome (ACS) and referred for PCI + stent implantation. Long-term all-cause mortality was compared between patients receiving 
peri-interventional anticoagulation with bivalirudin alone, heparin alone, or heparin + glycoprotein IIb/IIIa inhibitors (GPIs), respectively. The mean 
follow up was 58 ± 27 months.
results: From 1,201 consecutive patients undergoing PCI, 127 (10.6 %) patients received bivalirudin alone, 664 (55.3 %) patients heparin alone 
and 410 (34.1 %) patients heparin + GPIs. Out of a series of baseline variables the following were significantly different between groups: Age, gender, 
current smoking, peripheral vascular disease, renal failure, presence of atrial fibrillation, tumor anamnesis and baseline hemoglobin, respectively. In 
the cox proportional-hazards model peri-interventional anticoagulation with bivalirudin, as compared to heparin + GPIs, resulted in similar rates of 
all-cause death (HR 0.61, 95 % CI 0.33 to 1.14, p=0.12). However,anticoagulation with bivalirudin alone, as compared to heparin alone, resulted in 
significantly lower rates in all-cause mortality (HR 0.50, 95 % CI 0.27 to 0.9, p=0.02).
conclusions: In this single-center series of 1,201 consecutive “real world” patients undergoing PCI + coronary stenting, the use of bivalirudin, as 
compared to heparin + GPIs, was associated with comparable long-term all-cause mortality. However, the use of bivalirudin was superior to heparin 
alone with respect to all-cause death thus confirming the dominant role of bivalirudin monotherapy as anticoagulant strategy in ACS patients 
referred for PCI + stenting in a “real world” setting.
